Theriva Biologics (TOVX) News Today → This is the best new way to score with AI (From Weiss Ratings) (Ad) Free TOVX Stock Alerts $0.37 +0.00 (+0.81%) (As of 05:33 PM ET) Add Compare Share Share HeadlinesStock AnalysisChartEarningsHeadlinesInsider TradesShort InterestStock AnalysisChartEarningsHeadlinesInsider TradesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14 at 8:00 AM | globenewswire.comTheriva™ Biologics to Participate in the A.G.P. Virtual Healthcare ConferenceMay 8, 2024 | americanbankingnews.comTheriva Biologics (NYSEAMERICAN:TOVX) Trading Up 4.5%May 7, 2024 | investorplace.comTOVX Stock Earnings: Theriva Biologics Beats EPS for Q1 2024May 7, 2024 | globenewswire.comTheriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial ResultsApril 25, 2024 | investing.comTheriva reports progress in retinoblastoma treatment trialApril 25, 2024 | globenewswire.comTheriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 23, 2024 | globenewswire.comTheriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory RetinoblastomaApril 22, 2024 | globenewswire.comTheriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual MeetingApril 17, 2024 | benzinga.comTheriva Biologics Hits Several Milestones In 2023, Positioning Itself For Growth As The Firm Targets Difficult-To-Treat CancersApril 8, 2024 | finanznachrichten.deTheriva Biologics, Inc.: Theriva Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual MeetingApril 8, 2024 | globenewswire.comTheriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual MeetingMarch 27, 2024 | seekingalpha.comTheriva Biologics, Inc. (TOVX) Q4 2023 Earnings Call TranscriptMarch 26, 2024 | finance.yahoo.comQ4 2023 Theriva Biologics Inc Earnings CallMarch 25, 2024 | globenewswire.comTheriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial ResultsMarch 22, 2024 | benzinga.comPreview: Theriva Biologics's EarningsMarch 19, 2024 | finanznachrichten.deTheriva Biologics, Inc.: Theriva Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial ResultsMarch 19, 2024 | globenewswire.comTheriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial ResultsMarch 11, 2024 | globenewswire.comTheriva™ Biologics to Participate in the BIO-Europe Spring ConferenceFebruary 8, 2024 | msn.comTheriva Biologics Reports Positive Phase 2b Trial ProgressFebruary 8, 2024 | msn.comTheriva Biologics VIRAGE Trial Progresses PositivelyFebruary 7, 2024 | finance.yahoo.comTheriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal AdenocarcinomaJanuary 16, 2024 | finance.yahoo.comTheriva Biologics to Participate in the B. Riley Securities Annual Oncology ConferenceNovember 20, 2023 | finance.yahoo.comTheriva Biologics, Inc. (NYSE:TOVX) Q3 2023 Earnings Call TranscriptNovember 14, 2023 | finance.yahoo.comQ3 2023 Theriva Biologics Inc Earnings CallNovember 13, 2023 | msn.comTheriva Biologics GAAP EPS of -$0.19 beats by $0.23November 13, 2023 | finance.yahoo.comTheriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial ResultsNovember 10, 2023 | msn.comTheriva Biologics Q3 2023 Earnings PreviewNovember 10, 2023 | benzinga.comEarnings Outlook For Theriva BiologicsNovember 8, 2023 | morningstar.comTheriva Biologics Inc TOVXNovember 6, 2023 | finance.yahoo.comTheriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2023 Operational Highlights and Financial ResultsNovember 2, 2023 | finance.yahoo.comTheriva™ Biologics to Participate in the BIO-Europe ConferenceNovember 2, 2023 | finance.yahoo.comTheriva™ Biologics and Sant Joan de Déu-Barcelona Children’s Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat CancerOctober 23, 2023 | finance.yahoo.comTheriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023October 16, 2023 | finance.yahoo.comTheriva™ Biologics Announces Presentation at ESMO Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and NeckOctober 14, 2023 | wsj.comSamsung Biologics Co. Ltd.September 28, 2023 | finance.yahoo.comTheriva Biologics to Participate in the Emerging Growth ConferenceAugust 9, 2023 | finance.yahoo.comQ2 2023 Theriva Biologics Inc Earnings CallAugust 8, 2023 | washingtonpost.comTheriva Biologics: Q2 Earnings SnapshotAugust 8, 2023 | finance.yahoo.comTheriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial ResultsAugust 2, 2023 | finance.yahoo.comTheriva™ Biologics Announces Key Progress in VIRAGE, an Ongoing, Multinational Phase 2b Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal AdenocarcinomaAugust 1, 2023 | finance.yahoo.comTheriva Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2023 Operational Highlights and Financial ResultsJune 29, 2023 | benzinga.comTheriva Biologics Stock (AMEX:TOVX), DividendsJune 28, 2023 | theglobeandmail.comAnother Biotech Stealing The Premarket SpotlightJune 28, 2023 | msn.comWhy Theriva Biologics Shares Are Booming TodayJune 27, 2023 | marketwatch.comTheriva Gets Orphan Drug Designation for VCN-01 to Treat Pancreatic CancerJune 27, 2023 | msn.comTheriva shares rally amid FDA orphan drug designation for lead productMay 23, 2023 | finanznachrichten.deTheriva Biologics, Inc.: Theriva Biologics Announces Appointment of Ramon Alemany, Ph.D., to Senior Vice President of DiscoveryMay 23, 2023 | finance.yahoo.comTheriva Biologics Announces Appointment of Ramon Alemany, Ph.D., to Senior Vice President of DiscoveryMay 12, 2023 | finance.yahoo.comQ1 2023 Theriva Biologics Inc Earnings CallMay 11, 2023 | finanznachrichten.deTheriva Biologics, Inc.: Theriva Biologics Reports First Quarter 2023 Operational Highlights and Financial Results Get Theriva Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for TOVX and its competitors with MarketBeat's FREE daily newsletter. Email Address Look Who Fired the World’s Richest Man (Ad)This company is tiny… but already has contracts with 30 federal agencies and services some of the biggest companies in the U.S. And demand for the technology is unprecedented … “unlike anything we have seen in the past,” says a spokesman. Get the full story here. TOVX Media Mentions By Week TOVX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TOVX News Sentiment▼0.290.55▲Average Medical News Sentiment TOVX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TOVX Articles This Week▼30▲TOVX Articles Average Week Get Theriva Biologics News Delivered to You Automatically Sign up to receive the latest news and ratings for TOVX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: CANF News PCSA News RNAZ News KTTA News EMMA News UPC News SHPH News HEPA News TENX News PULM News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:TOVX) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyElon’s New Device is About to Shock the WorldInvestorPlaceGold ManiaStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theriva Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
